In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
|Slideshows|December 6, 2016
FDA Drug Approvals for Cancer in 2016
Author(s)Cancer Network Editors
This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.
Advertisement
Advertisement
Related to this article
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in KEYNOTE-365 cohort I.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Six-year NATALEE data show ribociclib plus an NSAI reduced the risk of death by 19% vs NSAI alone in HR+/HER2- early breast cancer.
Final NSABP B-42 data show 5 additional years of letrozole improved DFS, BCFI, and distant recurrence vs placebo at 15 years, with no OS difference.
Perioperative pembrolizumab plus neoadjuvant cisplatin and gemcitabine did not significantly improve EFS vs placebo in cisplatin-eligible MIBC in KEYNOTE-866.
Hope S. Rugo, MD, FASCO, and Irene M. Kang, MD, discussed ASCENT-03, -04, and TROPION-Breast02 data, sequencing, and toxicity in metastatic TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Perioperative Pembrolizumab Plus Chemo Does Not Significantly Improve EFS in MIBC
2
Adjuvant Ribociclib Improves OS at 6 Years in HR+/HER2- Early Breast Cancer
3
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
4
Extended Letrozole Sustains DFS Benefit at 15 Years in HR+ Breast Cancer
5